Introduction {#Sec1}
============

Osteoporosis in men is an increasing but under-appreciated clinical and public health problem with the lifetime risk of fracture in men at age 50 years estimated at 21% \[[@CR1]\]. As in women, increasing age is one of the major determinants of osteoporosis and fracture risk in men. Most studies examining changes in bone health with age have focused on "areal" bone mineral density (g/cm^2^; BMD~a~) \[[@CR2]\] as measured by dual-energy X-ray absorptiometry (DXA) \[[@CR3]--[@CR6]\]. There are limitations, however, in assessment of bone health using DXA. In particular, DXA tends to overestimate BMD in larger, and underestimate in smaller, bones. Furthermore, bone strength and susceptibility to fracture is influenced not only by the bone mineral content (BMC) but also bone shape and mineral distribution and the loading conditions to which the bone is subjected. Peripheral quantitative computed tomography (pQCT) allows assessment of both bone geometry and material properties including volumetric density (BMD). In contrast to age-related changes in DXA BMD~a~ in men there are relatively few data concerning change in BMD as assessed by pQCT and bone structure with age.

Levels of sex steroids are known to be associated with BMD~a~, as assessed using DXA, and also rate of bone loss \[[@CR7]--[@CR13]\]. The contribution of oestradiol (E~2~) to BMD has been reasonably well established but the effect of testosterone (T) is less clear, as are the effects of sex hormones on bone structural parameters. Khosla et al. \[[@CR9], [@CR14]\] showed that oestradiol (E~2~) was the most constant predictor of BMD and geometry, measured by QCT, with the effect being more marked in elderly men as age-related declines in sex steroids become relevant. Similarly in the MINOS cohort, E~2~ was related to DXA BMD~a~ cortical thickness and area \[[@CR15]\]. There is some evidence to suggest a threshold effect of oestrogen, particularly in cortical bone, below which the male skeleton may suffer oestrogen-related bone loss similar to that in the post menopausal female---the threshold level being the median value of bioavailable (bio) E~2~ (\<30 pM) in older (\>60 years) men \[[@CR8], [@CR14]\]. Testosterone (T) has been linked with cortical and trabecular BMD \[[@CR14], [@CR16]\] with conflicting data on effects on bone geometry. Some studies have observed an association between testosterone and bone loss in males \[[@CR13]\] whilst others have shown little or no effect, be it assessing BMD~a~ or increased fracture risk \[[@CR15], [@CR17]--[@CR19]\]; geometric parameters were not reported in these studies.

The aims of this cross-sectional study were: firstly to determine the influence of age on BMD and bone structure at the radius in middle-aged and elderly European men; secondly to determine the relationship between BMD and bone structure with sex steroid levels, and thirdly to determine whether the strength of any association between bioE~2~ and BMD differ above and below a threshold level of bioE~2~ defined as the median value among older men (60 years and over).

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

The subjects included in this analysis were recruited for participation in the European Male Ageing Study (EMAS), a prospective study of ageing in European Caucasian community-dwelling men. Detailed methods have been described previously \[[@CR20]\]. Briefly, men were recruited from population-based sampling frames in eight centres between 2003 and 2005. Stratified random sampling was used with the aim of recruiting equal numbers of men in each of four 10-year age bands: 40--49 years, 50--59 years, 60--69 years, and 70--79 years. Letters of invitation were sent to subjects asking them to attend for health assessments by a range of health questionnaires, physical and cognitive performance tests, anthropometry and a fasting blood sample. In two centres, Manchester (UK) and Leuven (Belgium) subjects had pQCT measurements performed at the radius. Ethics approval for the study was obtained in accordance with local institutional requirements in each centre, and each participant gave written informed consent.

Peripheral quantitative computed tomography {#Sec4}
-------------------------------------------

Peripheral QCT measurements of the non-dominant radius were made in men recruited to the Manchester and Leuven centres using XCT-2000 scanners (Stratec, Pforzheim, Germany). At the distal (4%) site total and trabecular BMD (mg/cm^3^) and bone cross-sectional area (mm^2^) were measured (voxel size, 0.4 mm); the slice location at the 4% and 50% site was more distal in Leuven compared with Manchester; the reference line was placed at the distal border of the radial endplate in Leuven, in Manchester the line is placed to bisect the lateral border of the endplate these differences result in a scan site difference approximately 1--2 mm between centers. At the diaphysis (50% site, voxel size 0.6 mm), cortical BMD (mg/cm^3^), cortical BMC (mg/mm), total, cortical and medullary areas (mm^2^), cortical thickness (mm), stress strain index (SSI, mm^3^) and muscle cross-sectional area, as a proxy for muscle strength (CSMA, mm^2^), were measured. SSI provides a measure of a bone's torsional strength \[[@CR21], [@CR22]\]. A detailed methodology for these measurements has been described previously \[[@CR23]\].

For cross-calibration between Leuven and Manchester the European Forearm Phantom (EFP) was measured \[[@CR24]\]; 10 repeat measurements were taken in slices 1--4. There were no differences greater than precision error for trabecular, total and cortical BMD, BMC or cortical area. Therefore no cross-calibration was performed between the two centres. These data and decisions were reviewed by Dr Klaus Engelke a CT expert from University of Erlangen, Germany and the scanner manufacturer Stratec Medizintechnik GmbH, Profzheim, Germany (Dr. Johannes Willnecker---personal communication).

The short term precision of two repeat radius measurements with repositioning in adults were: Manchester (*n* = 22) Leuven (*n* = 40) trabecular BMD 1.27%, 1.42%; total BMD 2.1%, 1.3%; cortical BMD 0.77%, 0.71%; cortical area 2.4%, 1.3%; muscle area 3.7%, 1.1%. Manufacturer's standard quality assurance procedures were followed in both centres.

Sex hormone measurement {#Sec5}
-----------------------

A single-fasting morning (before 10.00 h) venous blood sample was obtained from all subjects. Serum was separated immediately after phlebotomy and stored at −80°C until assay at the end of the baseline study. Measurement of T and E~2~ were carried out by gas chromatography mass spectrometry as described in Labrie et al. \[[@CR25], [@CR26]\]. The lower limit of T quantitation was 0.17 nmol/L and E~2~ was 7.34 pmol/L. The coefficients of variation of T measurements were 2.9% within runs and 3.4% between runs, and for E~2~, were 3.5% within runs and 3.7% between runs. SHBG was measured by the Modular E170 platform electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany) as previously described \[[@CR27]\]. Free and bioT and E~2~ levels were derived from total T, total E~2~, SHBG, and albumin concentrations using mass action equations and associations constants of Van Pottelbergh et al. and Vermeulen et al. \[[@CR12], [@CR28]\].

Statistical analysis {#Sec6}
--------------------

Linear regression was used to explore the association between age and various pQCT parameters as dependent variables; and the results expressed as unstandardised β coefficients and 95% confidence intervals. Regression analysis was also used to investigate the association between pQCT parameters and sex hormones (analysed as continuous variables) including total, free and bioavailable E~2~ and T. Adjustments were made in these analyses for age, height and weight as these variables were found to have significant independent associations with the pQCT parameters. We tested for a centre interaction for the hormone and pQCT regressions. For some parameters, there was a significant interaction and therefore our analyses were performed in each centre separately. Based on previous data suggesting an influence of age on the association between sex hormone status and pQCT parameters, the analysis was repeated after stratification by age (\<60 and \>60 years) \[[@CR14]\]. Subjects were categorised into those above or below a bioE~2~ threshold, defined as the median value in those over 60 years (51 pmol/L) and the association between bioE~2~ and BMD measurements (at both 4% and 50% sites) examined. All data from the two centres were analysed separately. Statistical analysis was performed using STATA version 9.2 (<http://www.stata.com>).

Results {#Sec7}
=======

Subject characteristics {#Sec8}
-----------------------

Three hundred thirty-nine men from Manchester and 389 from Leuven participated in this study. Their mean ages were 60.2 and 60.0 years, respectively. There were no differences in height or weight between subjects recruited in the two centres, but body mass index was slightly greater in Manchester (27.5 vs 26.9 kg/m^2^), see Table [1](#Tab1){ref-type="table"}. Cortical BMD and BMC at the midshaft, and also cross-sectional muscle area and SSI were significantly greater in subjects recruited in Leuven, Table [1](#Tab1){ref-type="table"}. At the distal radial (4%) site, radial area was greater in Leuven and total BMD lower in Leuven compared to Manchester, indicating the slightly different scan location (in more distal thus expanded radius site in Leuven). Table 1Subject characteristics: by centreVariableManchester *N* = 339Leuven *N* = 389Mean (SD)Mean (SD)Age at interview (years)60.2 (11.1)60.0 (11.1)Height (cm)174.3 (7.2)174.5 (7.1)Weight (kg)83.8 (13.4)82.1 (13.2)Body mass index (kg/m^2^)27.5 (3.6)26.9 (3.9)\*Midshaft radius Cortical BMD (mg/cm^3^)1,149.8 (39.8)1,161.0 (38.0)\* Cortical BMC (mg/mm)120.5 (18.0)124.0 (17.2)\* Total area (mm^2^)149.5 (21.5)150.5 (22.3) Cortical thickness (mm)3.2 (0.5)3.2 (0.4) Medullary area (mm^2^)43.4 (17.2)43.7 (18.9) Cross-sectional muscle area (mm^2^)3,558.3 (649.3)3,744.8 (591.6)\* Stress strain index (mm^3^)330.3 (63.4)345.6 (67.1)\*Distal radius Total density (mg/cm^3^)436.3 (70.1)361.1 (57.3)\* Total area (mm^2^)341.2 (52.5)413.1 (66.7)\* Trabecular density (mg/cm^3^)203.9 (48.0)205.5 (41.4)\**p* \< 0.05

Sex hormone levels in the different centres are presented in Table [2](#Tab2){ref-type="table"}. The mean serum T levels (total, free and bioavailable) were higher in Leuven than Manchester while the total, free and bioavailable E~2~ levels were lower. There was no difference in SHBG levels in the two centres. Table 2Sex hormone descriptives: by centreVariableManchester *N* = 339Leuven *N* = 389Mean (SD)Mean (SD)Testosterone (nmol/L)17.3 (6.2)18.6 (5.9)\*Free testosterone (pmol/L)306.1 (91.1)324.8 (88.6)\*Bioavailable testosterone (nmol/L)7.6 (2.3)8.2 (2.3)\*Oestradiol (pmol/L)80.4 (25.7)73.5 (24.2)\*Free oestradiol (pmol/L)1.4 (0.4)1.2 (0.4)\*Bioavailable oestradiol (pmol/L)56.4 (18.0)51.2 (17.0)\*SHBG (nmol/L)42.0 (18.2)43.7 (19.2)Reference range in healthy men aged 18--29 years for total testosterone measured by mass spectroscopy (MS) is 9--42 nmol/L and for calculated free testosterone 146--555 pmol/L \[[@CR36]\]. There are at present no published reference ranges for oestradiol measured by MS in healthy young men. Reference range in healthy men aged 20 years for SHBG measured by immunoassay is 13--53 nmol/L \[[@CR37]\]\**p* \< 0.05

Age-related variations in bone mass and geometry {#Sec9}
------------------------------------------------

At the 50% midshaft site, lower cortical BMD, BMC, thickness and muscle area, and greater medullary area were decreased with age. There were no age-related variations in bone strength as assessed by SSI, (Table [3](#Tab3){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}) at either study centre. There were small though non-significant increases in bone area with age. For all parameters the change with age was broadly linear across the age range with no evidence of accelerated loss in later life. At the distal radius, there was a negative association of both trabecular and total BMD with age in both centres, Fig. [1](#Fig1){ref-type="fig"}. Table 3Influence of age on pQCT parameters at the radius: by centreManchesterLeuvenβ co-efficient^a^ (95% CI)% change/yearβ co-efficient^a^ (95% CI)% change/yearMidshaft radiusCortical BMD−1.210 (−1.573, −0.846)\*−0.107−0.894 (−1.225, −0.562)\*−0.077Cortical BMC−0.290 (−0.462, −0.119)\*−0.271−0.260 (−0.414, −0.108)\*−0.208Total area0.176 (−0.032, 0.384)0.1190.060 (−0.142, 0.261)0.040Cortical thickness−0.010 (−0.014, −0.005)\*−0.319−0.007 (−0.010, −0.003)\*−0.219Medullary area0.310 (0.147, 0.473)\*0.8240.206 (0.036, 0.375)\*0.471Stress strain index−0.022 (−0.637, 0.593)−0.021−0.510 (−1.114, 0.094)−0.148CSMA^b^−20.561 (−26.464, −14.658)\*−0.567−14.763 (−19.908, −9.618)\*−0.394Distal radiusTotal density−1.847 (−2.498, −1.196)\*−0.446−1.665 (−2.157, −1.172)\*−0.461Total area0.413 (−0.094, 0.921)0.1140.501 (−0.102, 1.103)0.121Trabecular density−0.676 (−1.137, −0.216)\*−0.397−0.452 (−0.825, −0.079)\*−0.220\**p* \< 0.05^a^Change in each pQCT parameter per 1 year increase in age^b^Cross-sectional muscle areaFig. 1**a** Association between cortical BMD at the midshaft radius and age: by centre. **b** Association between stress strain index at the midshaft radius and age: by centre. **c** Association between cross-sectional muscle area at the midshaft radius and age: by centre. **d** Association between total density at the distal radius and age: by centre

Influence of sex hormones on pQCT parameters {#Sec10}
--------------------------------------------

The association between total, free, and bioavailable fractions of T and E~2~ with pQCT parameters were broadly similar. We present data here for the bioavailable hormone relationships (bioE~2~, bioavailable testosterone (bioT)) (Table [4](#Tab4){ref-type="table"}). In Leuven men, higher bioE~2~ was associated with increased cortical BMD at the 50% site and trabecular BMD at the 4% site; higher bioE~2~ was associated also with greater cortical thickness and smaller medullary area. There was no important effect of bioT on BMD at either site. BioT was positively associated with CSMA in the Leuven men. There were no significant associations with any of the skeletal parameters in the Manchester men other than a negative association between total area (4% site) and bioE~2~. Based on previous data \[[@CR14]\] suggesting an influence of age on the association between sex hormone status and pQCT parameters, we analysed men above and below 60 years separately. The data are presented in Table [5](#Tab5){ref-type="table"}. In Leuven men, all the significant associations observed in the unstratified analysis were observed exclusively in the older men. Furthermore, among Leuven men older than 60 years, a number of significant associations emerged that were not present in the unstratified analysis. There was a positive association between bioE~2~ and cortical BMC at the 50% site and total BMD at the 4% site. There were positive associations also between bioT and (1) cortical BMC and stress strain index at the 50% site and (2) total area at the 4% site. Table 4Influence of bioavailable testosterone and oestradiol on pQCT parameters at the radius: by centreManchesterLeuvenβ co-efficient^a^ (95% CI)β co-efficient^a^ (95% CI)Midshaft radiusCortical BMDBioT−0.427 (−2.505, 1.651)0.583 (−1.354, 2.519)BioE~2~−0.006 (−0.237, 0.225)0.393 (0.167, 0.618)\* Cortical BMC BioT0.235 (−0.676, 1.145)0.812 (−0.009, 1.633) BioE~2~−0.056 (−0.157, 0.046)0.094 (−0.002, 0.190) Total area BioT0.140 (−0.934, 1.214)0.511 (−0.590, 1.612) BioE~2~−0.072 (−0.191, 0.047)−0.107 (−0.236, 0.022) Cortical thickness BioT−0.002 (−0.026, 0.023)0.018 (−0.004, 0.040) BioE~2~−0.001 (−0.004, 0.002)0.004 (0.001, 0.006)\* Medullary area BioT0.028 (−0.840, 0.896)−0.160 (−1.145, 0.825) BioE~2~−0.030 (−0.127, 0.066)−0.156 (−0.272, −0.040)\* Stress strain index BioT1.090 (−2.139, 4.319)2.541 (−0.730, 5.812) BioE~2~−0.184 (−0.543, 0.175)−0.106 (−0.485, 0.274) CSMA^b^ BioT4.020 (−25.383, 33.424)31.382 (7.565, 55.198)\* BioE~2~−2.073 (−5.334, 1.188)1.099 (−1.733, 3.931)Distal radius Total density BioT0.288 (−3.397, 3.974)−0.472 (−3.261, 2.317) BioE~2~0.248 (−0.161, 0.656)0.259 (−0.069, 0.586) Total area BioT−0.295 (−2.994, 2.403)3.241 (−0.107, 6.590) BioE~2~−0.313 (−0.611, −0.015)\*0.134 (−0.263, 0.531) Trabecular density BioT0.590 (−2.043, 3.224)0.399 (−1.742, 2.540) BioE~2~0.087 (−0.206, 0.379)0.316 (0.064, 0.568)\*\**p* \< 0.05^a^Adjusted for age, height, and weight^b^Cross-sectional muscle areaTable 5Influence of bioavailable testosterone and oestradiol on pQCT parameters at the radius: by age and centreManchesterLeuvenAge \< 60Age ≥ 60Age \< 60Age ≥ 60β co-efficient^a^ (95% CI)β co-efficient^a^ (95% CI)β co-efficient^a^ (95% CI)β co-efficient^a^ (95% CI)Midshaft radius Cortical BMDBioT−1.282 (−3.559, 0.994)0.336 (−3.232, 3.905)−1.631 (−4.039, 0.778)3.117 (−0.072, 6.305)BioE~2~−0.046 (−0.319, 0.228)0.030 (−0.337, 0.397)0.107 (−0.182, 0.396)0.699 (0.348, 1.050)\* Cortical BMC BioT−0.116 (−1.233, 1.001)0.513 (−0.943, 1.970)0.031 (−1.104, 1.166)1.818 (0.576, 3.059)\* BioE~2~−0.146 (−0.278, −0.014)\*0.013 (−0.137, 0.163)0.006 (−0.126, 0.137)0.198 (0.057, 0.340)\* Total area BioT0.635 (−0.858, 2.127)−0.341 (−1.884, 1.201)0.147 (−1.371, 1.665)1.170 (−0.508, 2.848) BioE~2~−0.085 (−0.264, 0.093)−0.052 (−0.211, 0.106)−0.075 (−0.250, 0.100)−0.127 (−0.319, 0.064) Cortical thickness BioT−0.014 (−0.045, 0.017)0.008 (−0.029, 0.044)0.005 (−0.024, 0.034)0.035 (−0.002, 0.071) BioE~2~−0.003 (−0.006, 0.001)−0.050 (−0.184, 0.085)0.002 (−0.002, 0.005)0.006 (0.002, 0.010)\* Medullary area BioT0.578 (−0.559, 1.715)−0.437 (−1.746, 0.872)−0.044 (−1.269, 1.181)−0.153 (−1.803, 1.496) BioE~2~0.010 (−0.127, 0.147)−0.050 (−0.184, 0.085)−0.074 (−0.220, 0.071)−0.239 (−0.424, −0.054)\* Stress strain index BioT2.103 (−2.304, 6.511)−0.177 (−4.914, 4.559)−0.580 (−5.335, 4.174)6.186 (1.526, 10.846)\* BioE~2~−0.344 (−0.870, 0.183)−0.053 (−0.540, 0.434)−0.250 (−0.789, 0.288)0.078 (−0.461, 0.617) CSMA^b^ BioT27.979 (−14.973, 70.931)−25.644 (−65.546, 14.257)20.499 (−14.140, 55.137)49.118 (15.313, 82.922)\* BioE~2~−1.363 (−6.531, 3.806)−3.183 (−7.279, 0.913)2.933 (−1.173, 7.040)−0.489 (−4.405, 3.427)Distal radius Total density BioT−3.349 (−8.094, 1.396)3.623 (−2.008, 9.255)−1.617 (−5.374, 2.140)1.331 (−3.019, 5.680) BioE~2~0.223 (−0.347, 0.794)0.238 (−0.343, 0.818)−0.086 (−0.533, 0.360)0.639 (0.156, 1.121)\* Total area BioT1.536 (−2.117, 5.188)−2.362 (−6.361, 1.636)0.772 (−3.620, 5.165)6.111 (0.783, 11.440)\* BioE~2~−0.355 (−0.790, 0.080)−0.261 (−0.672, 0.150)0.354 (−0.163, 0.871)−0.106 (−0.719, 0.508) Trabecular density BioT−1.191 (−4.465, 2.083)2.566 (−1.640, 6.772)0.588 (−2.052, 3.228)0.136 (−3.412, 3.685) BioE~2~0.104 (−0.289, 0.497)0.092 (−0.342, 0.526)0.200 (−0.115, 0.516)0.420 (0.023, 0.817)\*\**p* \< 0.05^a^Adjusted for age, height, and weight^b^Cross-sectional muscle area

Influence of threshold level of bioavailable oestradiol {#Sec11}
-------------------------------------------------------

The median bioE~2~ in men (both centres combined) over 60 years was 51 pmol/L. Among the Leuven men, after adjusting for age, height, and weight there was a significant association between bioE~2~ and cortical BMD at the 50% site among those above and below this threshold. The magnitude of effect associated with trabecular BMD at the 4% site was broadly similar among those above and below the threshold, but because of smaller numbers neither association was statistically significant, see Table [6](#Tab6){ref-type="table"}. There was no association between bioE~2~ and BMD in either compartment in Manchester men. Table 6Influence of bioavailable oestradiol on BMD at the radius in Leuven, Belgium (≥60 years): by median bioavailable oestradiol levelBioavailable oestradiol (pmol/L)BioE2 \< 51 pmol/LBioE2 ≥ 51 pmol/LOverallβ co-efficient^a^ (95% CI)β co-efficient^a^ (95% CI)β co-efficient^a^ (95% CI)Midshaft radiusCortical BMD (mg/cm^3^)1.550 (0.584, 2.516)\*0.698 (0.059, 1.338)\*0.699 (0.348, 1.050)\*Distal radiusTotal density (mg/cm^3^)0.020 (−1.340, 1.380)0.783 (−0.079, 1.645)0.639 (0.156, 1.121)\*Trabecular density (mg/cm^3^)0.410 (−0.740, 1.561)0.516 (−0.156, 1.187)0.420 (0.023, 0.817)\*\**p* \< 0.05^a^Adjusted for age, height, and weight

Discussion {#Sec12}
==========

Our data confirm evidence of age-related change at the midshaft radius in cortical BMD and BMC, cortical thickness and medullary area in middle-aged and elderly men. Among older Leuven men oestrogen appeared to play a role in maintaining BMD. BioT had no effect on BMD, but may influence bone health through an effect on muscle mass and bone area.

Our data confirm that there is lower BMC, thinner cortex and larger medullary area at the radial diaphysis, and also a lower muscle area in ageing men. Despite the lower BMC and muscle area with ageing it is possible bone strength is maintained through periosteal apposition (indicated by marginally greater bone area in older men). These data are consistent with those previously reported at the distal site, with loss of trabecular and total BMD \[[@CR29]\] and a gain of bone on the periosteal surface. The periosteal apposition at this site has been shown to maintain strength and may be one reason why the incidence of forearm fracture is lower in men (than women) \[[@CR30]\]. Taking muscle area as a surrogate for loading, it is plausible that the small adaptations in bone geometry can maintain strength to the level required for reduced loading from muscles.

Evidence from observational and clinical studies support the view that oestrogen is the most important sex steroid in determining bone mass in men \[[@CR7]--[@CR12]\]. Our finding of a positive relationship between E~2~ and BMD at both the 4% and 50% sites in the Leuven men is consistent with this view. The association with bioE~2~ was stronger in the older, than the younger, men which would be consistent with a lower level of bioavailable hormone in older age. Khosla et al. reported evidence of a threshold level of bioE~2~ (30 pM) above which no association with oestrogen was observed in cortical BMD, but not trabecular, bone at a range of skeletal sites (femoral neck, distal radius, and distal tibia) \[[@CR14]\]. The threshold used, defined as the median value in men age 60 years, differed from the value used in our study (51 pmol/L) which was based on mass spectrometry measurements. Our data do not support these observations of a threshold effect of bioE~2~ on cortical bone.

The current view is that testosterone acts on bone primarily via aromatisation to estrogens. There is some evidence, at least in rats, that T may increase periosteal apposition (and thereby increase total area), and certainly in adolescents T increases periosteal growth. Szulc et al. using data from DXA, suggested an increase in periosteal apposition with age though not via an action of T \[[@CR15], [@CR31]\]. In contrast, Khosla et al. found an inverse association in men with higher levels of T linked with reduced bone area \[[@CR14]\]. Our results (both centres) showed no significant change in bone area with increasing testosterone at the 50% site though there was a positive association at the 4% site among the older Leuven men.

One of the intriguing findings was the differences in the absolute pQCT parameters between the two centres and the relationships with sex steroids. Subjects in both centres were recruited using the same methods and were from a similar socioeconomic background. Removing subjects (*n* = 18) who were taking medications known to influence sex steroid levels did not change the results. Further adjustment for smoking and physical activity had no effect on these relationships. The lower total BMD and larger bone area in Leuven at the 4% site may in part be related to the slightly different and more distal slice location used at the two centres. It is unlikely, however, that this difference in protocol explains centre differences at the 50% site due to the more homogenous structure of the radius at this anatomical site. It is therefore likely that other explanations, including genetic and environmental factors, play a role in these Manchester--Leuven skeletal and hormone differences. Genetic factors are known to influence both bone mass and structure at the radius. Data from family and twin studies suggest that genetic factors explain about 50% of the variation in the radius total and trabecular vBMD, and up to 40% of cortical vBMD \[[@CR32], [@CR33]\]. In addition, a large proportion of the variation in geometric parameters such as radius cross-sectional area (27%) and cortical thickness (51%) are also attributable to genetic factors \[[@CR33]\]. Variations in other skeletal parameters across Europe have previously been reported \[[@CR34]\]; however, to the best of our knowledge, there are no data concerning pQCT parameters. We cannot explain the variation in findings in relation to the associations between bone parameters and sex hormones, other than the slight difference in protocol using pQCT which we feel would be unlikely to explain the variation. The similarity in rate of change with age for the skeletal parameters in both centres provides some construct validity to these measures.

The strength of our study was that it was population based and used pQCT measurements to obtain information not only on bone density but also bone morphology. There are some limitations which need to be considered when interpreting the results. The response rate for participation in the study was 45% \[[@CR20]\]. Those who participated may have differed with respect to bone health and/or sex hormone status than those who did not participate. However, the main findings, in relation to the sex steroid levels were based on internal comparisons among responders and so selection factors are unlikely to have had an important effect. One of the key factors in designing the study was to ensure standardisation of the study instruments used in the different participating centres. Hormone measurements were performed in a central reference laboratory to minimise assay variability. The same pQCT scanner type and model was used in each centre and after testing scanner differences with the EFP, no cross-calibration was necessary. There was a small difference in the 4% and 50% site location between centres, Leuven being 1--2 mm more distal in position than Manchester, as evidenced by a larger radial area and a lower total BMD in Leuven compared to Manchester. This emphasizes the need to have very precise and detailed protocols, including an image of the position of the reference line, for performing single-slice pQCT in multiple centres; quite large differences in the measured parameters can be observed in the 4% site, even in adjacent slices \[[@CR35]\]. Although this may explain differences in BMD and area at the 4% site between centres, it is unlikely to affect the relationship between these parameters and sex hormones at the 50% site. Our study was cross-sectional: to determine true age-related changes in bone health prospective data are needed. The results were also obtained from a predominantly Caucasian European population so cannot be extrapolated beyond this setting.

In conclusion, there is evidence of age-related change at the midshaft radius in cortical BMD and BMC, cortical thickness and medullary area in middle-aged and elderly European men. Among older men, bioE~2~ may play a role in maintaining cortical and trabecular BMD. BioT has no effect on BMD but may influence bone health through an effect on muscle mass and bone area.
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